New drug HX111 targets advanced cancers in early trial
Disease control
Not yet recruiting
This study tests a new drug called HX111 in people with advanced solid tumors or lymphoma that has not responded to other treatments. The trial has two parts: first, finding the safest dose, and then checking how well it works. About 70 adults aged 18 to 70 with a life expectancy…
Phase: PHASE1, PHASE2 • Sponsor: Hanx Biopharmaceuticals (Wuhan) Co., Ltd. • Aim: Disease control
Last updated May 04, 2026 16:24 UTC